VOLITIONRX LIMITED 13,000,000 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • June 5th, 2023 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 13,000,000 shares of its common stock, par value $0.001 per share (the “Shares”). The 13,000,000 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,950,000 Shares (the “Option Shares”). The Firm Shares and, if and to the extent such option or any Underwriter Warrant (as defined below) is exercised, the Option Shares and Underwriter Warrant Shares (as defined below), are collectively called the “Offered Shares.” The Offered Shares and Underwriter Warrants are hereinafter referred to together as the “Securities.” Prime Executions, Inc. dba Freedom Capital Markets (“Freedom”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offerin
UNDERWRITING AGREEMENTUnderwriting Agreement • February 21st, 2023 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
The undersigned, VolitionRx Limited, a company incorporated under the laws of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of VolitionRx Limited, the “Company”), hereby confirms its agreement (this “Agreement”) with Newbridge Securities Corporation (the “Underwriter” or “Newbridge”) on the terms and conditions set forth herein.
3,769,231 Shares* VOLITIONRX LIMITED Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 18th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 3,769,231 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 3,769,231 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 565,384 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” Raymond James & Associates, Inc. is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
VOLITIONRX LIMITED COMMON STOCK EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • September 10th, 2018 • Volitionrx LTD • In vitro & in vivo diagnostic substances
VolitionRx Limited, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc., as follows:
EXHIBIT (6)(A)(I) TRANSFER AGENT AND REGISITRAR AGREEMENT THIS AGREEMENT made and entered into this 10th day of April, 1999, by and between: NEVADA AGENCY AND TRUST COMPANY, 50 West Liberty Street, Suite 880, Reno, Nevada 89501, hereinafter called...Transfer Agent and Regisitrar Agreement • December 6th, 1999 • Standard Capital Corp • Nevada
VOLITIONRX LIMITED STOCK OPTION AGREEMENTStock Option Agreement • November 18th, 2011 • Volitionrx LTD • Mining & quarrying of nonmetallic minerals (no fuels) • Delaware
Unless otherwise defined herein, capitalized terms shall have the meaning set forth in the VolitionRX Limited 2011 Equity Incentive Plan (the "Plan").
4,365,000 Shares* VOLITIONRX LIMITED Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 22nd, 2020 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), an aggregate of 4,365,000 shares of its Common Stock, par value $0.001 per share (the “Common Stock”). The aggregate of 4,365,000 shares to be purchased from the Company are called the “Firm Shares.” In addition, the Company has agreed to sell to the Underwriters, upon the terms and conditions stated herein, up to an additional 654,750 shares of Common Stock (the “Additional Shares”) to cover over-allotments by the Underwriters, if any. The Firm Shares and the Additional Shares are collectively referred to in this Agreement as the “Shares.” National Securities Corporation is acting as the representative of the several Underwriters and in such capacity is referred to in this Agreement as the “Representative.”
VOLITIONRX LIMITED STOCK AWARD AGREEMENT FOR RESTRICTED STOCKVolitionrx LTD • November 18th, 2011 • Mining & quarrying of nonmetallic minerals (no fuels) • Delaware
Unless otherwise defined herein, capitalized terms shall have the defined meaning set forth in the VolitionRX Limited 2011 Equity Incentive Plan.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 12th, 2024 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 8, 2024, between VolitionRx Limited, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
THIS AGREEMENT is dated 10th April 2017 PARTIESAgreement • May 11th, 2017 • Volitionrx LTD • In vitro & in vivo diagnostic substances • England and Wales
This agreement supersedes and replaces in its entirety the existing consultancy agreement between DCV Solutions Limited and VolitionRx Limited, for the services of the Employee, dated March 6, 2017.
and - CONSULTANCY AGREEMENTConsultancy Agreement • January 23rd, 2015 • Volitionrx LTD • In vitro & in vivo diagnostic substances • Delaware
VOLITIONRX LIMITED incorporated and registered in the State of Delaware, USA, whose principal place of business is at 1 Scotts Road, #24-05 Shaw Centre, Singapore, 228208 (“Volition”); and
Exhibit 10.1 TRANSFER AGENT AND REGISITRAR AGREEMENT TRANSFER AGENT AND REGISITRAR AGREEMENT --------------------------------------- THIS AGREEMENT made and entered into this 10th day of April, 1999, by and between: NEVADA AGENCY AND TRUST COMPANY, 50...Agent and Regisitrar Agreement • November 10th, 2005 • Standard Capital Corp • Mining & quarrying of nonmetallic minerals (no fuels) • Nevada
VOLITIONRX LIMITED COMMON STOCK EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • May 20th, 2022 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC (the “Agent”), as follows:
DATED 22 September 2010 SINGAPORE VOLITION Pte LIMITED and VALIRX PLCVolitionrx LTD • May 8th, 2012 • Mining & quarrying of nonmetallic minerals (no fuels)
ValiRx PLC (incorporated and registered in England and Wales under company number 3916791 the registered office of which is at 24 Greville Street, London EC1N 8SS (the "Seller"); and
VOLITIONRX LIMITED [•] SHARES OF COMMON STOCK UNDERWRITING AGREEMENTUnderwriting Agreement • February 4th, 2015 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRX Limited, a Delaware corporation (the “Company”) proposes, subject to the terms and conditions stated herein, to issue and sell to National Securities Corporation and Lake Street Capital Markets, LLC and each of the other Underwriters named in Schedule VII hereto, if any (each, an “Underwriter” and collectively, the “Underwriters”), an aggregate of [•] fully paid shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] shares (the “Additional Shares” and together with the Firm Shares, the “Securities”) of the Company’s $0.001 par value common stock (the “Common Stock”).
Patent License AgreementPatent License Agreement • February 24th, 2012 • Volitionrx LTD • Mining & quarrying of nonmetallic minerals (no fuels)
IMPERIAL COLLEGE INNOVATIONS LIMITED (“Innovations”), a company incorporated in England and Wales whose principal place of business is at 12th Floor, Electrical Engineering Building, Imperial College, London SW7 2AZ; and
Terms & Conditions of Employment for Executive OfficerVolitionrx LTD • February 24th, 2012 • Mining & quarrying of nonmetallic minerals (no fuels)
It is agreed that the Company will employ the Executive, and the Executive will work for the Company, on the following terms and conditions:
EXECUTIVE EMPLOYMENT AGREEMENT CAMERON REYNOLDSExecutive Employment Agreement • January 23rd, 2015 • Volitionrx LTD • In vitro & in vivo diagnostic substances • Delaware
This Employment Agreement ("Agreement") is dated January 01, 2015 (“Execution Date”) and made effective as of January 01, 2015 (“Effective Date”) between VolitionRx Limited, a Delaware corporation ("Company"), and Cameron Reynolds ("Executive"). The Company and Executive are sometimes referred to herein individually as a “Party” and collectively as the “Parties.
VOLITIONRX LIMITED EMPLOYMENT AGREEMENT CORPORATE SECRETARYVolitionrx Limited Employment Agreement • January 23rd, 2015 • Volitionrx LTD • In vitro & in vivo diagnostic substances • Delaware
This Employment Agreement ("Agreement") is dated January 01, 2015 (“Execution Date”) and made effective on January 01, 2015 (the “Effective Date”) by and between VolitionRx, Limited, a Delaware corporation ("Company") and Rodney Rootsaert ("Employee"). The Company and Employee are sometimes referred to herein individually as a “Party” or collectively as the “Parties.
WARRANT AGREEMENTWarrant Agreement • February 7th, 2020 • Volitionrx LTD • In vitro & in vivo diagnostic substances • Delaware
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS WILL HAVE BECOME EFFECTIVE WITH REGARD THERETO, OR (ii) AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN CONNECTION WITH SUCH OFFER, SALE OR TRANSFER. AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.
THIS AMENDING AGREEMENT dated 31 July 2006 is between:Amending Agreement • January 11th, 2012 • Volitionrx LTD • Mining & quarrying of nonmetallic minerals (no fuels)
FIRST AMENDMENT TO CONSULTANCY AGREEMENTConsultancy Agreement • May 13th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances
This First Amendment to Consultancy Agreement (the “Amendment”) is dated this 11th day of May 2016 between VolitionRx Limited, a Delaware corporation (“Volition”), and Borlaug Limited, a Private Limited Company incorporated under the laws of England and Wales (“Borlaug”).
Agreement no. 5852 relative to a repayable advance on the diagnosis of colorectal cancer by nucleosomics.Volitionrx LTD • January 11th, 2012 • Mining & quarrying of nonmetallic minerals (no fuels) • Wallonia
Patent Licence AgreementPatent Licence Agreement • January 11th, 2012 • Volitionrx LTD • Mining & quarrying of nonmetallic minerals (no fuels)
Certain patents, intellectual property, know-how and technical data collectively known as the Intellectual Property Rights (IPR) were licensed to ValiRx PLC (ValiRx) through the Patent License Agreement dated 03 October 2007 from Chroma Therapeutics Limited, a Company registered in England and Wales under Company number 04066289 whose principal place of business is 93 Milton Park, Abingdon, Oxon OX14 4RY.
SALE AGREEMENTSale Agreement • May 13th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances
The Belgian société anonyme “Gérard Dekoninck”, abbreviated to “GDK”, registered in the Belgian companies database [Banque Carrefour des Entreprises] under number 0425.908.489, whose registered office is located at 22 rue Phocas Lejeune, 5032 Gembloux (Les Isnes), Belgium, registered for value-added tax under number 425.908.489, and incorporated by means of a deed executed by the notary Michel DUCHATEAU in Liège on 28 June 1984, extracts of the minutes of which were published in appendix to the Moniteur Belge on 24 July 1984 under number 2351-28, and whose articles of association have been amended on a number of occasions, most recently under the terms of the minutes of an Extraordinary General Meeting drawn up by Maître Damien LE CLERCQ, a notary in Namur, on 9 November 2010, published in appendix to the Moniteur Belge on 26 January 2011 under number 11013596,
Patent Licence AgreementPatent Licence Agreement • January 11th, 2012 • Volitionrx LTD • Mining & quarrying of nonmetallic minerals (no fuels) • England and Wales
Certain patents, intellectual property, know-how and technical data collectively known as the Intellectual Property Rights (IPR) were licensed to ValiPharma (formally known as Cronos Therapeutics Ltd) through the Patent License Agreement (as amended) dated 19 October 2005 from Imperial Innovations Limited (formerly known as Imperial College Innovations Limited), a Company registered in England and Wales under Company number 02060639 whose principal place of business is 52 Princess Gate, Exhibition Road, London, SW7 2PG.
SINGAPORE VOLITION PTE. LIMITED EMPLOYMENT AGREEMENT GROUP CHIEF EXECUTIVE OFFICEREmployment Agreement • March 15th, 2023 • Volitionrx LTD • In vitro & in vivo diagnostic substances
This Employment Agreement (“Agreement”) is dated March 13, 2023 (“Execution Date”) and is effective from March 01, 2023 (the “Effective Date”) by and between Singapore Volition Pte. Limited, a Singapore corporation (“Company” or “We”) and Cameron Reynolds (“Employee” or “You”). The Company and Employee are sometimes referred to herein individually as a “Party” or collectively as the “Parties.
VOLITION DIAGNOSTICS UK LIMITED EMPLOYMENT AGREEMENT GROUP GENERAL COUNSELRestricted Stock Unit Agreement • November 10th, 2021 • Volitionrx LTD • In vitro & in vivo diagnostic substances • England and Wales
This Employment Agreement (“Agreement”) is dated August 23, 2021 (“Execution Date”), by and between Volition Diagnostics UK Limited, incorporated and registered in England and Wales with company number 09871726, with its office located at 93-95 Gloucester Place, London, W1U 6JQ (“Company”) and Nick Plummer (“Employee”). The Company and Employee are sometimes referred to herein individually as a “Party” or collectively as the “Parties.
Agreement Between Isosceles Finance Limited And VolitionRX LimitedHeads of Agreement Agreement • January 23rd, 2015 • Volitionrx LTD • In vitro & in vivo diagnostic substances • Delaware
This agreement “Agreement”, dated 2nd May 2014 is made between Isosceles Finance Limited (Isosceles) registered office: 20-22 Bedford Row, London, WC1R 4JS and VolitionRX Limited (VolitionRX) address: 1 Scotts Road, #24-05 Shaw Centre, Singapore, 228208.
VOLITIONRX LIMITED EMPLOYMENT AGREEMENT CHIEF FINANCIAL OFFICERVolitionrx Limited Employment Agreement • March 11th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
This Employment Agreement ("Agreement") is dated August 11, 2015 (“Execution Date”) and made effective on August 17, 2015 (the “Effective Date”) by and between VolitionRx, Limited, a Delaware corporation ("Company") and David Kratochvil ("Employee"). The Company and Employee are sometimes referred to herein individually as a “Party” or collectively as the “Parties.
EXECUTIVE CHAIRMAN’S AGREEMENTChairman’s Agreement • May 12th, 2015 • Volitionrx LTD • In vitro & in vivo diagnostic substances • Delaware
This EXECUTIVE CHAIRMAN’S AGREEMENT is dated March 31, 2015 (the “Agreement”) by and between VOLITIONRX LIMITED, a Delaware corporation (the “Company”), and DR. MARTIN CHARLES FAULKES, an individual resident in the United Kingdom (“Dr. Faulkes”).
VOLITIONRX LIMITED 2,250,000 SHARES OF COMMON STOCK UNDERWRITING AGREEMENTAgreement • September 30th, 2016 • Volitionrx LTD • In vitro & in vivo diagnostic substances • New York
VolitionRx Limited, a Delaware corporation (the “Company”) proposes, subject to the terms and conditions stated herein, to issue and sell to the several Underwriters named in Schedule VI hereto (each, an “Underwriter” and collectively, the “Underwriters”), for whom National Securities Corporation is acting as representative (the “Representative”), an aggregate of 2,250,000 authorized but unissued shares (the “Firm Shares”) of its Common Stock, par value $0.001 per share (the “Common Stock”) and, at the election of the Underwriters, upon the terms and conditions stated herein, up to an additional 337,500 shares of Common Stock (the “Additional Shares” and together with the Firm Shares, the “Securities”).
COMMON STOCK PURCHASE AGREEMENT by and between VolitionRx Limited and Cotterford Company Limited August 8, 2018Common Stock Purchase Agreement • August 9th, 2018 • Volitionrx LTD • In vitro & in vivo diagnostic substances • Delaware
This Common Stock Purchase Agreement (this “Agreement”) dated as of August 8, 2018 is made by and between VolitionRx Limited, a Delaware corporation, (the “Company”), and Cotterford Company Limited (the “Purchaser”).
Master Consultancy Services Agreement (October 2010 revision)Master Consultancy Services Agreement • January 23rd, 2015 • Volitionrx LTD • In vitro & in vivo diagnostic substances
OncoLytika Ltd a company incorporated in England & Wales (registration number 07305115) whose registered office and trading address is at 1 The Firs, Wilburton, Ely, Cambridgeshire CB6 3FL (‘the Consultancy’), and
CONSULTING SERVICES AGREEMENTConsulting Services Agreement • November 12th, 2020 • Volitionrx LTD • In vitro & in vivo diagnostic substances
THIS CONSULTING AGREEMENT (this “Agreement”), is entered into as of December 1, 2020 (the “Effective Date”) by and between Singapore Volition Pte. Limited, a Singapore corporation with its office located at 111 Somerset Road, Level 3, TripleOne Somerset, Singapore 238164 (the “Company”) and PB Commodities Pte. Ltd, a Singapore corporation with its registered office located at 165 Gangsa Road, Unit 01-70, Singapore 670165 (the “Consultant”).
